Grant of Options

RNS Number : 0939K
ValiRx PLC
11 July 2011
 



11 July 2011

ValiRx Plc (AIM: VAL)

("ValiRx" or the "Company")

 

Grant of options

 

 

ValiRx, a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that on 8 July 2011 it granted 42,500,000 options over ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") to certain employees and directors of the Company, as set out in the table below.

 

 

Name of director

Number of shares held

% of issued share capital

Number of existing options

 

Number of new options granted

 

Total options now held

Options held as % of issued share capital

 

Satu Vainikka

16,644,221

1.59%

1,000,000

10,000,000

11,000,000

1.05%

Nick Thorniley

8,213,035

0.79%

400,000

6,000,000

6,400,000

0.61%

George Morris

11,409,944

1.09%

750,000

6,000,000

6,750,000

0.65%

Gerry Desler

6,154,761

0.59%

400,000

6,000,000

6,400,000

0.61%

Kevin Alexander

2,688,750

0.26%

400,000

6,000,000

6,400,000

0.61%

Oliver de Giorgio-Miller

Nil

Nil

Nil

3,000,000

3,000,000

0.29%








Total Directors

45,110,711

4.32%

2,950,000

37,000,000

39,950,000

3.82%








Other employees

Nil

Nil

600,000

5,500,000

6,100,000

0.59%








Total

45,110,711

4.32%

3,550,000

42,500,000

46,050,000

4.41%

 

 

The new options were granted under the Company's stock option plan and have an exercise price of  0.75 pence. The new options are exercisable between 8 July 2011 and 7 July 2021.

 

Following the grant of the new options, the total number of Ordinary Shares under option held by directors which could be issued is 39,950,000 Ordinary Shares, representing approximately 3.8 per cent. of the current issued share capital of the Company.

 

In addition, a further 5,500,000 options have been granted to employees of the Company at an exercise price of 0.75 pence which are exercisable until 7 July 2021.

 

The issued share capital of the Company comprises 1,044,562,609 ordinary shares of 0.1 pence each.

 

For more information, please contact:

 

ValiRx plc

www.ValiRx.com

Dr Satu Vainikka

Tel: +44 (0) 20 3008 4416



Cairn Financial Advisers LLP


Nominated Adviser

Tel:+44 (0) 20 7148 7900

Liam Murray / Avi Robinson




Hybridan LLP


Broker

Tel: +44 (0) 20 7947 4350

Claire Noyce




Peckwater PR

Tel: +44 (0)7879 458 364

Tarquin Edwards

tarquin.edwards@peckwaterpr.co.uk

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBUGDRLUGBGBI

Companies

Valirx (VAL)
UK 100

Latest directors dealings